Amgen's Money-Back Guarantee
March 17 2017 - 2:00PM
Dow Jones News
By Charley Grant
For insurance companies, drug stock investors, and the
president, price matters.
Amgen served as a reminder on Friday. New clinical data from the
biotech giant show its anti-cholesterol drug Repatha, when used in
combination with statins, caused a 20% reduction in deaths, strokes
and heart attacks, compared to traditional statin therapy. However,
the data do not show a meaningful reduction in cardiovascular
mortality rates for patients on Repatha.
The data are strong in an absolute sense, but left investors
disappointed. Amgen shares were down more than 7% Friday morning,
after having rallied by about 23% this year. Smaller biotech
companies developing similar drugs fell as much as 20% Friday.
One reason: insurers will weigh the data against Repatha's
price. The drug costs more than $14,500 annually before rebates and
discounts. A statin, meanwhile, has a minimal cost. That dynamic
has weighed on Repatha sales since the drug's launch in 2015.
To help win over those insurers, Amgen made an unusual public
offer of refunds if patients on the drug suffer a heart attack or
stroke. That is a sensible step to boost sales given Friday's data
and the rising pressure that drug makers are feeling on prices from
insurers and from President Donald Trump.
While Amgen has signed deals with insurers offering discounts on
Repatha if the drug doesn't perform, the drug maker took it a step
further by offering its guarantee in the company's press release
that announced the data. The company's refund offer to insurers
could make paying for performance a more accepted way to balance
drug prices with their value.
For Amgen, even the refund offer may not bring insurers on board
given the drug's failure to improve in cardiovascular mortality
outcomes, according to analysts at Robert W. Baird & Co. As
such, Amgen will have an uphill battle to meet Wall Street's
revenue expectations for the drug. Analyst consensus calls for more
than $3 billion in annual sales by 2022, according to FactSet.
Amgen has booked less than $150 million in cumulative drug sales
since approval.
Those projections are counting on Repatha to generate
essentially all of Amgen's revenue growth through 2022. Sales of
Amgen's current best-selling product, the anti-inflammatory drug
Enbrel, are expected to fall 20% over that period as the product
ages.
The good news: Amgen trades at less than 14 times forward
earnings, more or less on par with most of its large biotech and
pharma peers. That should keep Friday's slide from turning into a
prolonged slump. However, Friday's results suggest that investors,
just like health plans, are more likely to pay for performance in
the future.
Until then, Amgen's sharp rally to start the year is likely to
be put on hold.
Write to Charley Grant at charles.grant@wsj.com
(END) Dow Jones Newswires
March 17, 2017 13:45 ET (17:45 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2024 to May 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From May 2023 to May 2024